Cross-source evidence timeline
Degarelix research timeline
Follow 63 selected, directly cited source records from December 24, 2008 through November 17, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.↗
PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 2027 · month precisionAdded to PeptideScanner November 17, 2026Clinical trials
ClinicalTrials.gov record NCT03689699↗
PeptideScanner retained ClinicalTrials.gov record NCT03689699 at 2026-11-15T21:52:09.579Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
[Treatment of advanced hormone-sensitive prostate cancer using degarelix].↗
PubMed lists PMID 34907463 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2021-12-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 14, 2021 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Resting state functional connectivity in paedophilic disorder and degarelix treatment.↗
PubMed lists PMID 41918172 in Acta neuropsychiatrica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 1, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer.↗
PubMed lists PMID 41970125 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-03-10 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 10, 2026 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.↗
PubMed lists PMID 38413843 in The Prostate as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-27 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 27, 2024 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.↗
PubMed lists PMID 24568188 in Journal of medical economics as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-02-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 25, 2014 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT00117286↗
PeptideScanner retained ClinicalTrials.gov record NCT00117286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.↗
PubMed lists PMID 35923949 in Frontiers in public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 18, 2022 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT03069937↗
PeptideScanner retained ClinicalTrials.gov record NCT03069937 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-10-15, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Degarelix acetate for the treatment of prostate cancer.↗
PubMed lists PMID 20069136 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-10 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 2009 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Degarelix for treating advanced hormone-sensitive prostate cancer.↗
PubMed lists PMID 34350976 in The Cochrane database of systematic reviews as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2021-08-05 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 5, 2021 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01220869↗
PeptideScanner retained ClinicalTrials.gov record NCT01220869 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-04-13, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey.↗
PubMed lists PMID 21768273 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2011-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 18, 2011 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker.↗
PubMed lists PMID 23589543 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2013-04-15 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 15, 2013 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2024
Clinical trials
ClinicalTrials.gov record NCT05181800↗
PeptideScanner retained ClinicalTrials.gov record NCT05181800 at 2026-11-15T21:52:09.579Z. Its registry update date was 2024-09-27, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.↗
PubMed lists PMID 28480768 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2017-05-19 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 19, 2017 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Evaluation of degarelix in the management of prostate cancer.↗
PubMed lists PMID 21188095 in Cancer management and research as Journal Article, with publication-date metadata of 2010-01-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 25, 2010 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2023
Clinical trials
ClinicalTrials.gov record NCT00818623↗
PeptideScanner retained ClinicalTrials.gov record NCT00818623 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00819156↗
PeptideScanner retained ClinicalTrials.gov record NCT00819156 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-30, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00819247↗
PeptideScanner retained ClinicalTrials.gov record NCT00819247 at 2026-11-15T21:52:09.579Z. Its registry update date was 2023-11-09, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Investigation of the GnRH antagonist degarelix isomerization in biological matrices.↗
PubMed lists PMID 37455491 in Pharmacology research & perspectives as Journal Article, with publication-date metadata of 2023-08 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 2023 · month precisionAdded to PeptideScanner November 15, 2026
Source year
2022
Literature metadata
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.↗
PubMed lists PMID 34934969 in European urology open science as Journal Article, with publication-date metadata of 2021-11-17 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 17, 2021 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT04397718↗
PeptideScanner retained ClinicalTrials.gov record NCT04397718 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-06-06, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands.↗
PubMed lists PMID 35069083 in Current urology as Journal Article, with publication-date metadata of 2021-06-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 25, 2021 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.↗
PubMed lists PMID 29264358 in Research and reports in urology as Journal Article, with publication-date metadata of 2017-12-06 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 6, 2017 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02849990↗
PeptideScanner retained ClinicalTrials.gov record NCT02849990 at 2026-11-15T21:52:09.579Z. Its registry update date was 2022-01-13, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2021
Literature metadata
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermitten…↗
PubMed lists PMID 29534997 in The Journal of urology as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2018-03-11 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 11, 2018 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01751451↗
PeptideScanner retained ClinicalTrials.gov record NCT01751451 at 2026-11-15T21:52:09.579Z. Its registry update date was 2021-11-19, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02489357↗
PeptideScanner retained ClinicalTrials.gov record NCT02489357 at 2026-11-15T21:52:09.579Z. Its registry update date was 2021-11-12, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Degarelix as a new antiangiogenic agent for metastatic colon cancer?↗
PubMed lists PMID 23431078 in World journal of gastroenterology as Case Reports, Journal Article, with publication-date metadata of 2013-02-07 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 7, 2013 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Tipping the balance in favour of degarelix for ADT.↗
PubMed lists PMID 24473414 in Nature reviews. Urology as Journal Article, with publication-date metadata of 2014-01-28 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 28, 2014 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
A Real-Time NMR Method for Measurement of In Vitro Aggregation Kinetics Of Degarelix Drug Products.↗
PubMed lists PMID 33586081 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2021-02-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 14, 2021 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2020
Literature metadata
Prostate Cancer Drug Degarelix Rapidly Treats Pedophilic Disorder.↗
PubMed lists PMID 32573666 in JAMA as Journal Article, with publication-date metadata of 2020-06-23 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 23, 2020 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2019
Literature metadata
An efficient synthesis of deuterium-labeled degarelix acetate, a third-generation gonadotropin-releasing hormone receptor antagonist.↗
PubMed lists PMID 28960413 in Journal of labelled compounds & radiopharmaceuticals as Journal Article, with publication-date metadata of 2018-03-15 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 15, 2018 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01696877↗
PeptideScanner retained ClinicalTrials.gov record NCT01696877 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-03-28, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01731912↗
PeptideScanner retained ClinicalTrials.gov record NCT01731912 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-01-18, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2018
Literature metadata
Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.↗
PubMed lists PMID 28753747 in European urology focus as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-01-22 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 22, 2016 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2017
Literature metadata
A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.↗
PubMed lists PMID 27756786 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 18, 2016 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02135445↗
PeptideScanner retained ClinicalTrials.gov record NCT02135445 at 2026-11-15T21:52:09.579Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2015
Literature metadata
Degarelix: an antagonist to GnRH--theoretical and treatment considerations in paraphilia.↗
PubMed lists PMID 22082230 in The journal of sexual medicine as Letter, with publication-date metadata of 2011-11-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 14, 2011 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.↗
PubMed lists PMID 25851250 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-04-08 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 8, 2015 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00947882↗
PeptideScanner retained ClinicalTrials.gov record NCT00947882 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-06-08, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00527488↗
PeptideScanner retained ClinicalTrials.gov record NCT00527488 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-05-04, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00215683↗
PeptideScanner retained ClinicalTrials.gov record NCT00215683 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-04-01, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2014
Literature metadata
In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.↗
PubMed lists PMID 21496210 in Basic & clinical pharmacology & toxicology as Journal Article, with publication-date metadata of 2011-05-23 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 23, 2011 · day precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00801242↗
PeptideScanner retained ClinicalTrials.gov record NCT00801242 at 2026-11-15T21:52:09.579Z. Its registry update date was 2014-09-03, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2013
Literature metadata
Degarelix (firmagon) for prostate cancer.↗
PubMed lists PMID 19838145 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2009-10-19 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 19, 2009 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Management of a patient with locally advanced prostate cancer with degarelix: a case report.↗
PubMed lists PMID 23783053 in The Canadian journal of urology as Case Reports, Journal Article, with publication-date metadata of 2013-06 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 2013 · month precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01215513↗
PeptideScanner retained ClinicalTrials.gov record NCT01215513 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-05-22, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00451958↗
PeptideScanner retained ClinicalTrials.gov record NCT00451958 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-03-21, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01071915↗
PeptideScanner retained ClinicalTrials.gov record NCT01071915 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00738673↗
PeptideScanner retained ClinicalTrials.gov record NCT00738673 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-18, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00967018↗
PeptideScanner retained ClinicalTrials.gov record NCT00967018 at 2026-11-15T21:52:09.579Z. Its registry update date was 2013-01-03, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2012
Clinical trials
ClinicalTrials.gov record NCT00295750↗
PeptideScanner retained ClinicalTrials.gov record NCT00295750 at 2026-11-15T21:52:09.579Z. Its registry update date was 2012-12-19, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2011
Clinical trials
ClinicalTrials.gov record NCT00116779↗
PeptideScanner retained ClinicalTrials.gov record NCT00116779 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-12-19, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00117949↗
PeptideScanner retained ClinicalTrials.gov record NCT00117949 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-05-23, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00468286↗
PeptideScanner retained ClinicalTrials.gov record NCT00468286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-03-23, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2010
Clinical trials
ClinicalTrials.gov record NCT00268892↗
PeptideScanner retained ClinicalTrials.gov record NCT00268892 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-24, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00116753↗
PeptideScanner retained ClinicalTrials.gov record NCT00116753 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-10, and PeptideScanner's reviewed identity mapping was degarelix.↗
Added to PeptideScanner November 15, 2026Regulatory
Federal Register notice 2010-4159↗
The Federal Register published notice 2010-4159, attributed to FDA and its parent HHS department, on 2010-03-01. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRMAGON,” and PeptideScanner's exact reviewed identity mapping connects the document to Degarelix.↗
Added to PeptideScanner November 15, 2026
Source year
2009
Literature metadata
Degarelix for prostate cancer.↗
PubMed lists PMID 19453267 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2009-06 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 2009 · month precisionAdded to PeptideScanner November 15, 2026
Source year
2008
Regulatory
Drugs@FDA application NDA022201↗
The official Drugs@FDA dataset lists original submission 1 for NDA 022201 with status AP dated 2008-12-24, and names degarelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026